Atamparib (RBN-2397)

Catalog No.S8993 Batch:S899302

Print

Technical Data

Formula

C20H23F6N7O3
Molecular Weight 523.43 CAS No. 2381037-82-5
Solubility (25°C)* In vitro DMSO 100 mg/mL (191.04 mM)
Ethanol 13 mg/mL (24.83 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Atamparib (RBN-2397) is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. RBN-2397 has the potential for the research of tumor treatment.
Targets
PARP7 [1]
(Cell-free assay)		 PARP7 [1]
(Cell-free assay)
<0.001 μM(Kd) <3 nM
In vitro

RBN-2397 restores cytosolic nucleic acid sensing and blocks cell proliferation in a human lung cancer cell line.[1]
In vivo

RBN-2397 causes complete regressions in human NSCLC NCI-H1373 xenografts and dose-dependent pharmacodynamic effects. RBN-2397 induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses.[1]

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    NCI-H1373 human lung cancer cells

  • Concentrations

    0.4 nM to 1000 nM

  • Incubation Time

    24 h

  • Method

    --
Animal Study:

[1]
  • Animal Models

    CB17 SCID mice with NCI-H1373 xenografts, CT26 tumor-bearing BALB/c mice

  • Dosages

    300 mg/kg, 100 mg/kg, 30 mg/kg, 10 mg/kg, 3 mg/kg

  • Administration

    Oral gavage

Selleck's Atamparib (RBN-2397) has been cited by 1 publication

Dendritic Cell - Fibroblast Crosstalk via TLR9 and AHR Signaling Drives Lung Fibrogenesis [ bioRxiv, 2024, 2024.03.15.584457] PubMed: 38559175

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.